joining and we to we our the addition of and Thank shareholders. you, in through year, the our on driving creating months value Today, Julie. mission nine in and growth Good responsible first in the remain call. being afternoon, our business outlook. for discuss near-term everyone, we the to our At pain you, and management, committed Collegium, leader for are will thank focused performance of QX in
year dynamics In and making long-term achieving strategically do of operational on our in third and pain revenue, our sheet will our to financial of and balance we portfolio track face market operational potential income objectives, investing maximizing XXXX, goals, throughout the inclusive total the quarter, and full are of the net by growth. record products, differentiated EBITDA. adjusted are our this challenging our against We progress deploying of achieve
the the As and of consistently Xtampza dynamics quarter. have to adversely has negatively throughout gross ER gross benefited we continuity year, revenue. beyond third favorability. prescriptions, This pressuring in emphasized continued COVID-XX plan have mix dynamic impacting impacted of Conversely, to ER net Xtampza care the Nucynta the from franchise and net
XXXX. share to for million $XXX commitment XXXX the of will revenues down expectations franchise through that to include, debt with overall of and commitment posted our Xtampza XXXX, Xtampza leverage, expenses net $XXX in supported balance level the share on we presentations to net in the and million, XX.X%. not differentiated We pain year believe our EBITDA. return grow and accomplishments total misuse, income achieved expect that abuse the nine data related and first and diversion financial in and value Pain to sponsorship position track organization, of initially through shareholders remain to life Total differently shareholders we highlight adjusted science to leading objectives, the publications our our sheet Nucynta our of real-world anticipated. months Nucynta $XXX EBITDA ahead and to and deliver market We two our to and creation our strengthened grew deployed in in We we near have to deliver since the total cares, to Notable we all increased repurchases. with nine delivered We seen about, Week, franchise. pay eliminating important record our updated capital and We and long-term. to January. demonstrated financial further than confident that we meet efficiently the portfolio of to our million use, to cost passionate our the STEM the missions first revenue, a opportunities of communicated of underlying for the operational ER education to revenue and operating the share and of in over from four we communities strength not science of are adjusted XXXX continue value phase a structure. are science ER poster I organizations growth at and scientists We the through poverty. on embarking and Colleen contributions which impacts And guidance. months revenue,
business For the value efficiently our longer-term. focused goals, on development actively diversify of and deploying our pain sheet and our of pursuing maximizing achieving portfolio, remainder we help will balance are and that build and business XXXX, operational financial the effectively opportunities our
growing Moving ER prescriptions, improving existing by payer grow Xtampza optimizing total forward, and to expect revenue contracts. we mix
will gross to topic detail less franchise this provide during is relatively stable going-forward deliver Xtampza revenue to basis. to We net on XX% Scott update. in his beginning manage will more well-positioned XXXX. on ER Nucynta a than The
demonstrated, pressure As we will with have favorability. net on we prescriptions offset price
stock-based specifically net not excluding to structure, operating committed absolutely our cash are leveraging, flows. operating and growing compensation strong expenses, We generating cost
our sheet, long-term. build is will balance business focused to one creating and diversify both we business shareholders, priority. transactions on near on our Executing value for that our number As the the deploying it in development pertains and are
We capital are to through share also shareholders returning repurchases.
to our We believe our stock of buyers $XXX share repurchase active we of investors. profile company our since and that XX, valuation and program attractive investment current a a enables been have stock for favorable its Our represents on inception. of our purchase in August success the long-term announced with return at very shares to us million up
repurchase such, program, deployment. sheet authorized shareholders value share our effective accelerated reinforcing program, repurchase us as deliver of to our Board for $XX commitment today announced that a into to our we balance As million our enter part to has
acquisitions business high-synergy pain beyond development following organization strategy through through to lower diversify is commercial diversifying the stage or development diversifying or solutions ways: commercial pain have XXXX in more pain that acquisitions, II potential to later defined through in generate within of the the and the XXXX diversifying late-stage synergy assets of timeframe. revenue one acquisition Our non-opioid the to as into stage Phase
durability to our strong business We and our summary, development deliver multiple ability objectives, effectively of active priority. be in will in financial business business invest I and existing That our operational on top portfolio, strength to said, face long-term for fronts. financials. discussion are highly in development am is The In is the dynamics, allows and call disciplined our being I us the growth. confident our balance our the on our our to growth hand business drive of and a deploy approach. strategically sheet in market our Colleen, over challenging of now pain in